Some good news for the end of the week:

Thorofare, NJ, USA - September 9, 2005 Akers Biosciences, Inc. (LSE: AKR) is
delighted to announce the final conclusion to the legal matter, which had been
pending in the United States District Court, Southern District of Florida since
February, 2004.

On September 1, 2005, after a jury trial lasting six days, a final judgment was
entered in the matter of Akers vs. Alliance, wherein 'Judgment is hereby
entered on behalf of Counter-defendant, Akers Biosciences, Inc., and against
the counter-claimant, Alliance Investment Management, LTD. on all of
counter-claimant's claims, and counter-claimant shall take nothing from this
action.'

As a result, Akers Biosciences will recognize, as income in the current year,
the $713,046, which is the amount of previously due loan plus all related
interest and costs, now annulled under the terms of the Court Order.

Figures due on the 8th and have been ticking better all week within a sea of Red.
10/- sold @ 17p and now three mm's on the 'bid' Staying with them for the time being.

Akers Biosciences reveals a maiden profit of $1m for the year to the end of December.

Revenues rose to $6.1m from $5.5m in 2007 with adjusted EBITDA of $2.7m against a loss of $1.4m previously and a strong cash position of $4.3m.

Chairman Edward Mulhare said: "The company is finally evolving into the business that we long believed it could become. Each of the four current and two future core products have market potentials ranging from tens of millions of dollars per annum to hundreds of millions. We recognise that sales at present represent only a tiny fraction of the potential market size for each product and, having made inroads to commercialisation in 2008, the company is poised to accept the challenge to grow ABI's worldwide business in 2009 and beyond."

The new French decree requiring EACH car be equipped with TWO disposable alcohol detectors is a pain in the but except for Akers Biosciences who make them. What's the betting that the rest of Europe will follow?

Interview with Thomas Nicolette, President & CEO of Akers Biosciences.
As was previously announced in 2012 communications, the Company negotiated an exclusive, multi‐year breathalyser distribution and supply agreement with Chubeworkx, to take advantage of the French market opportunity, including a $1 million licensing fee.

Click the link below to listen;
Webcast

Nice movement in these over the last 30 days.

Like a skyrocket on back of slightly old news about Nasdaq listing but greatly helped by Henderson's taking out a large CFD for over 6% recently.

Serious question Mike , what happens when they close ?

Henderson got a CFD for 27% of a company I hold , think it might be Netplay.

Dil; It will collapse pretty quickly if they sell but a lot of funds are now using this as a money route, well its stays off their investmnet books so they can play the markets more !!!!

Interesting though that L & G closed their declared position so have to assume Henderson picked them up somehow via a cfd, bit messy though.

Short term punt me thinks

with nearly 400% rise in 6 weeks I am taking some profits.